Current and historical daily PE Ratio for Organon & Co (
) from 2021 to Apr 27 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. Organon & stock (OGN) PE ratio as of Apr 27 2024 is 4.64.
More Details
Organon & Co (OGN) PE Ratio (TTM) Chart
Organon & Co (OGN) PE Ratio (TTM) Historical Data
View and export this data going back to 2021. Start your Free Trial
Total 744
- 1
- 2
- 3
- 4
- 5
- 6
- 9
| Organon & PE Ratio (TTM) Historical Data | |||
|---|---|---|---|
| Date | PE Ratio (TTM) Data | Date | PE Ratio (TTM) Data |
| 2024-04-27 | 4.6 | 2024-02-23 | 4.6 |
| 2024-04-26 | 4.6 | 2024-02-22 | 4.6 |
| 2024-04-25 | 4.6 | 2024-02-21 | 4.6 |
| 2024-04-24 | 4.7 | 2024-02-20 | 4.6 |
| 2024-04-23 | 4.6 | 2024-02-16 | 4.7 |
| 2024-04-22 | 4.5 | 2024-02-15 | 4.7 |
| 2024-04-19 | 4.5 | 2024-02-14 | 4.1 |
| 2024-04-18 | 4.5 | 2024-02-13 | 4.0 |
| 2024-04-17 | 4.5 | 2024-02-12 | 4.2 |
| 2024-04-16 | 4.5 | 2024-02-09 | 4.1 |
| 2024-04-15 | 4.4 | 2024-02-08 | 4.1 |
| 2024-04-12 | 4.4 | 2024-02-07 | 4.1 |
| 2024-04-11 | 4.6 | 2024-02-06 | 4.2 |
| 2024-04-10 | 4.5 | 2024-02-05 | 4.0 |
| 2024-04-09 | 4.6 | 2024-02-02 | 4.2 |
| 2024-04-08 | 4.5 | 2024-02-01 | 4.3 |
| 2024-04-05 | 4.5 | 2024-01-31 | 4.2 |
| 2024-04-04 | 4.5 | 2024-01-30 | 4.2 |
| 2024-04-03 | 4.5 | 2024-01-29 | 4.3 |
| 2024-04-02 | 4.5 | 2024-01-26 | 4.2 |
| 2024-04-01 | 4.6 | 2024-01-25 | 4.2 |
| 2024-03-28 | 4.7 | 2024-01-24 | 4.1 |
| 2024-03-27 | 4.6 | 2024-01-23 | 4.1 |
| 2024-03-26 | 4.5 | 2024-01-22 | 3.9 |
| 2024-03-25 | 4.5 | 2024-01-19 | 3.9 |
| 2024-03-22 | 4.5 | 2024-01-18 | 3.9 |
| 2024-03-21 | 4.6 | 2024-01-17 | 4.0 |
| 2024-03-20 | 4.5 | 2024-01-16 | 4.2 |
| 2024-03-19 | 4.5 | 2024-01-12 | 4.2 |
| 2024-03-18 | 4.5 | 2024-01-11 | 4.2 |
| 2024-03-15 | 4.6 | 2024-01-10 | 4.3 |
| 2024-03-14 | 4.6 | 2024-01-09 | 4.0 |
| 2024-03-13 | 4.6 | 2024-01-08 | 4.1 |
| 2024-03-12 | 4.6 | 2024-01-05 | 3.6 |
| 2024-03-11 | 4.6 | 2024-01-04 | 3.5 |
| 2024-03-08 | 4.6 | 2024-01-03 | 3.7 |
| 2024-03-07 | 4.6 | 2024-01-02 | 3.7 |
| 2024-03-06 | 4.5 | 2023-12-29 | 3.6 |
| 2024-03-05 | 4.4 | 2023-12-28 | 3.6 |
| 2024-03-04 | 4.3 | 2023-12-27 | 6.3 |
| 2024-03-01 | 4.4 | 2023-12-26 | 6.2 |
| 2024-02-29 | 4.3 | 2023-12-22 | 6.1 |
| 2024-02-28 | 4.5 | 2023-12-21 | 5.9 |
| 2024-02-27 | 4.5 | 2023-12-20 | 5.7 |
| 2024-02-26 | 4.4 | 2023-12-19 | 5.9 |
Organon & Co (OGN) PE Ratio (TTM) Comparison
| Company | Market Cap(Mil) | PE Ratio (TTM) |
|---|
Business Description
Business Description
Organon & Co
NAICS : 325412
SIC : 2834
ISIN : US68622V1061
Share Class Description:
OGN: Ordinary SharesDescription
Organon & Co is a science-based global pharmaceutical company that develops and delivers health solutions through a portfolio of prescription therapies within women's health, biosimilars, and established brands. The Company's operations include the following product portfolio: Women's health, Biosimilars, and Established medicines. Geographically, it derives a majority of its revenue from Europe and Canada followed by the United States and then Asia Pacific and Japan. The company generates the majority of its revenue from the Established Brands product portfolio.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers